AbCellera Biologics
ABCL
86 hedge funds and large institutions have $2.42B invested in AbCellera Biologics in 2021 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 19 closing their positions.
126% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 19
65% more call options, than puts
Call options by funds: $2.35M | Put options by funds: $1.42M
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
39% more funds holding
Funds holding: 62 → 86 (+24)
1.16% more ownership
Funds ownership: 25.65% → 26.81% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
12% less capital invested
Capital invested by funds: $2.74B → $2.42B (-$324M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$90.5M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$46M |
| 3 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$41.8M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$41.7M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWG
Alpha Wave Global
New York
|
-$54.9M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$24.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$20.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$18.4M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$18.3M |
ABCL Hedge Fund Activity: Q1 2021 in Review
86 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2021, worth a combined $2.42B — down 12% from $2.74B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ABCL positions and 19 closed out — a net gain of 24 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $90.5M. The largest seller was Alpha Wave Global, cutting an estimated $54.9M.
- 86 institutional investors held AbCellera Biologics (ABCL) as of Q1 2021, up from 62 in Q4 2020.
- Funds reported $2.42B of AbCellera Biologics stock for Q1 2021, down 12% quarter-over-quarter.
- 43 funds opened new AbCellera Biologics positions in Q1 2021 and 19 closed out, a net change of +24 holders.
- The largest AbCellera Biologics buyer in Q1 2021 was Credit Suisse, an estimated $90.5M added.
- The largest AbCellera Biologics seller in Q1 2021 was Alpha Wave Global, an estimated $54.9M sold.
Based on aggregated 13F filings for Q1 2021.